Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensinconverting enzyme inhibitors is not beneficial: Results of a placebo-controlled, double-blind study

Dorszewski, A.; Gohmann, Ekbert; Dorszewski, Barbara; Werner, Gerald S.; Kreuzer, H; Figulla, Hans R.

doi:10.1016/s1071-9164(97)90040-3

Cited by 25 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…α-adrenolityki nie są zalecane w celu obniżania ciśnienia tętniczego z powodu wątpliwości dotyczą-cych braku bezpieczeństwa w HFrEF (aktywacja neurohormonalna, retencja płynów, pogorszenie HF) III A [458,464,465] diltiazem i werapamil nie są zalecane w celu obniżenia ciśnienia tętniczego ze względu na swój ujemny wpływ inotropowy i ryzyko pogorszenia HF…”

Section: Niedobór żElaza I Niedokrwistośćunclassified

“…Dlatego należy go wykluczyć u męż-czyzn z HF i pogarszaniem ich funkcji. Leki α-adrenolityczne powodują obniżenie ciśnienia, a także retencję sodu oraz wody i nie są bezpieczne u pacjentów z HFrEF [458,464,465]. Z tych powodów inhibitory 5-α-reduktazy są zasadniczo preferowane w leczeniu rozrostu prostaty u pacjentów z niewydolnością serca.…”

Section: Piśmiennictwo Potwierdzające Zaleceniaunclassified

See 1 more Smart Citation

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

460

446

View full text Add to dashboard Cite

Section: Niedobór żElaza I Niedokrwistośćunclassified

Section: Piśmiennictwo Potwierdzające Zaleceniaunclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

460

446

View full text Add to dashboard Cite

“…Fifteen reported no significant differences between medication and placebo [39,63,78,89,101,106,107,111,129,133,139,141,146,149,165]. Four studies were terminated early, two because of a trend towards increased mortality in the treatment arm [112,158], one because of significantly increased survival in the treatment arm [125] and one for reasons not outlined [147].…”

Section: Pharmacological Trialsmentioning

confidence: 99%

Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review

Morgan

McGee

Shelley

2007

European Journal of Cardiovascular Prevention & Rehabilitat

View full text Add to dashboard Cite

The increasing prevalence and poor prognosis associated with heart failure have prompted research to focus on improving quality of life (QoL) for heart failure patients. Research from 1996–2005 was systematically reviewed to identify randomized controlled trials that assessed QoL in heart failure. In 120 studies, 44 were medication trials; 19 surgical/procedural interventions; and 57 patient care/service delivery interventions. Studies were summarized in terms of aim, population, QoL measures used and QoL findings. Studies used 47 different measures of QoL-generic, health-related, condition-specific, domain-specific and utility measures. Most used a single QoL measure. In 87%, a condition specific QoL measure was used, with the Minnesota Living with Heart Failure Questionnaire being the favoured assessment tool. The range of QoL measures in use poses challenges for development of cumulative knowledge. Although comparability across studies is important, this must be informed by the responsiveness of the instrument selected. As carried out in other cardiac groups, comparative evaluations of instrument responsiveness are needed in heart failure. Eur J Cardiovasc Prev Rehabil 14:589-607 © 2007 The European Society of Cardiology

show abstract

“…Moxonidine increased mortality in patients in the MOXCON trial in HFrEF [11] and there are concerns of the risk in HFrEF patients of neurohormonal activation, fluid retention and worsening HF with alphaadrenoceptor antagonists. [12][13][14] Lastly in the setting of acute heart failure (AHF) i.v. nitrates (or sodium nitroprusside, starting with 0.3 μg/kg/min and increasing up to 5 μg/kg/min) are recommended to lower blood pressure.…”

Section: The Steps To Good Bp Control In Heart Failurementioning

confidence: 99%

The Management of Co-Morbidities in Patients with Heart Failure – Hypertension

Coats¹,

Rosano

Lopatin

2017

ICFJ

View full text Add to dashboard Cite

The 2016 ESC/HFA HF guidelines carry an important section on the treatments of co- morbidities in HF. Foremost of these in terms of frequency and its relevance to the aetiology of HF, especially HFpEF is hypertension. In this artcile we will review what the recent guidelines say about the management of hypertension in the setting of HF, both HFrEF and HFpEF and expand on some of the practical advice.

show abstract

Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensinconverting enzyme inhibitors is not beneficial: Results of a placebo-controlled, double-blind study

Cited by 25 publications

References 15 publications

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review

The Management of Co-Morbidities in Patients with Heart Failure – Hypertension

Contact Info

Product

Resources

About